Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.

Benzaquen, Michael (2020). Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma. Dermatologic therapy, 33(3), e13325. Wiley-Blackwell 10.1111/dth.13325

[img] Text
dth.13325.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (469kB) | Request a copy

Regarding the rising incidence and the not negligible mortality, the treatment of cutaneous squamous-cell carcinoma (cSCC) has a high clinical relevance. Immune checkpoint inhibitors (ICI), especially anti-programmed cell death-1 receptor (anti-PD-1) antibodies such as pembrolizumab and cemiplimab have shown promising results in Phase 2 studies for patients with locally advanced and/or metastatic cSCC. We are presenting a review of the latest results in the treatment of cSCC with ICI. Patients with locally advanced or metastatic cSCC have been treated with cemiplimab 3 mg/kg every 2 weeks. For locally advanced cSCC, an objective response was observed in 44% of patients, 13% patients with a complete response, and 31% with a partial response. For metastatic patients, the overall response rate was 49.2%. The approved dose for cemiplimab in the United States and Europe is 350 mg every 3 weeks. These ICI seem to achieve higher response rates compared with epidermal growth factor receptor (EGFR) inhibitors, with a durable response superior to both chemotherapy and EGFR inhibitors. The side effect profile of anti-PD-1 antibodies appears to be favorable compared to chemotherapy. In this way, PD-1 inhibitors are expected to become the new gold-standard treatment for patients with locally advanced and metastatic cSCC.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Benzaquen, Michael Joseph

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1396-0296

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

05 Jan 2021 11:20

Last Modified:

05 Jan 2021 11:20

Publisher DOI:

10.1111/dth.13325

PubMed ID:

32208547

Uncontrolled Keywords:

advanced cutaneous squamous-cell carcinoma anti-PD-1 antibodies cemiplimab immune checkpoint inhibitors pembrolizumab

BORIS DOI:

10.48350/149501

URI:

https://boris.unibe.ch/id/eprint/149501

Actions (login required)

Edit item Edit item
Provide Feedback